Norwegian Biotech Announces Positive Phase I Results for T cell-Stimulating Vaccine – Labiotech.eu (blog)
|
Norwegian Biotech Announces Positive Phase I Results for T cell-Stimulating Vaccine
Labiotech.eu (blog) PCI Biotech's T cell-stimulating vaccine enhances the cellular immune response, supporting it as a candidate for use alongside cancer vaccines. PCI Biotech, based in Oslo, Norway, has seen … photochemical internalization (PCI) technology. A … |
